Oncology

Single-cell method identifies core stem cells that cause leukemia within a tumor.

Ruptured cancerous cells are able to repair themselves to prevent cell death.

Study finds need for improved understanding of the association between rising systemic therapy use and the uptake of palliative care.

Cancer’s long-term side effects on fertility should be discussed with parents of young cancer patients.

Top news of the day from across the health care landscape.

Avella Specialty Pharmacy has launched two innovative apps to help providers select the most appropriate specialty drug options for hepatitis C and oncology patients.

Medical androgen deprivation therapies combined with other treatments may cause relapse in patients with prostate cancer.

Inhibiting GCN5 enzyme may lead to reduced remission risks and improved cure rates.

While PSA levels decreased in patients, overall survival did not improve in patients with non-metastatic prostate cancer.

Venetoclax (Venclexta)is the first treatment approved by the FDA that inhibits the B-cell lymphoma 2 (BCL-2) protein.

A flood of new therapies approved last year offer new hope for patients with multiple myeloma.

New technique allows physicians to see if a tumor is susceptible or resistant to treatment much earlier than conventional methods.

Atezolizumab treats locally advanced or metastatic NSCLC expressing the PD-L1 protein.

Top news of the day across the health care landscape.

Atezolizumab was previously granted Breakthrough Therapy Designation for NSCLC in February 2015.

Low oxygen conditions encourage some cancer stem cells to multiply.

Recent advances and updates in oncology and cancer drug development.

Experimental drug could may lead to new treatments for AML, lung cancer, brain cancer, and melanoma.

Only 20% of lung cancer patients show a response to current immunotherapeutic antibodies.

Study finds that manufacturers need to develop a new approach to engaging oncologists.

Top stories of the day from across the health care landscape.

SAMMSON gene thought to play an important role in the etiology of melanoma.

Combining drug trametinib with a superagonist can stimulate activity while preserving the cancer-blocking effects of the treatment.

Plant produces compounds that treat cancer, arrhythmia, and other medical problems.

HDAC inhibitors in combination with immune-stimulating agents improve tumor response.

New technique could soon move to clinical trials in prostate cancer.

Individualized approach allows for creation of widespread models of patient-specific tumors.

DNA screening technology up to 10,000 times more sensitive than current tests for cancer and HIV.